Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Cyclerion Therapeutics Inc's CYCN preclinical studies demonstrated its lead soluble guanylate cyclase (sGC) stimulator, CY6463, improved cellular energetics and reduced inflammation in preclinical models of mitochondrial disease.
The data will be presented at the International Conference on cGMP.
CY6463 significantly increased ATP levels in lymphoblasts derived from patients with mitochondrial complex 1 deficiency (Leber hereditary optic neuropathy or Leigh syndrome).
CY6463 restored mitochondrial gene expression in lymphoblasts derived from patients with mitochondrial complex 1 deficiency (Leber hereditary optic neuropathy or Leigh syndrome)
CY6463 significantly decreased the astrocytic marker, GFAP, linked to inflammation in a mouse model of mitochondrial complex 1 deficiency
The poster also mentioned that healthy, Leigh, and LHON patient cells that do not have a baseline ATP deficit did not increase ATP in response to CY6463.
Price Action: CYCN shares are up 10.4% at $0.52 during the market session on the last check Friday.

Momentum83.85

GrowthNot Available

QualityNot Available

Value67.14

Short

Medium

Long